The commencement of the Phase IIa trial of AZD9412 (formally SNG001) by AstraZeneca following the global license agreement in June 2014 is very encouraging. Data is expected in early 2017. We look forward to the data and in the meantime maintain our 49p price target and Buy recommendation.
22 Jul 2015
AZD9412 commences Phase IIa trial in severe asthma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AZD9412 commences Phase IIa trial in severe asthma
Synairgen plc (SNG:LON) | 5.1 0 (-0.7%) | Mkt Cap: 10.3m
- Published:
22 Jul 2015 -
Author:
Sheena Berry -
Pages:
3
The commencement of the Phase IIa trial of AZD9412 (formally SNG001) by AstraZeneca following the global license agreement in June 2014 is very encouraging. Data is expected in early 2017. We look forward to the data and in the meantime maintain our 49p price target and Buy recommendation.